Latest news with #IndianPharmaceuticalAlliance
Economic Times
07-08-2025
- Business
- Economic Times
Executive order by US administration excludes Pharma sector from immediate tariff imposition: Indian Pharmaceutical Alliance
Synopsis The Indian pharmaceutical sector has been excluded from immediate US tariff hikes due to the importance of generic medicines for affordable healthcare in the United States. This follows President Trump's imposition of a 25% tariff on India over Russian oil purchases, raising the total tariff to 50%. ANI "Executive order by US administration excludes Pharma sector from immediate tariff imposition": Indian Pharmaceutical Alliance The Indian pharmaceutical sector has been "excluded" from the immediate US tariff imposition, as generic medicines are "important" for affordable healthcare in the United States, said Sudarshan Jain, Secretary General of the Indian Pharmaceutical Alliance, on Wednesday. This comes after US President Donlad trump imposed an additional 25 per cent tariff on India over the continued purchase of Russian oil. Jain, says, "The recent Executive Order by the US Administration excludes the pharmaceutical sector from immediate tariff imposition. The sector is being reviewed under the Section 232 investigation. Generic medicines are important for affordable healthcare in the US and typically operate on razor-thin margins. Ensuring their consistent availability is critical for patient care" "India-US partnership is key to securing API supply chains and enhancing healthcare resilience," he noted. On Wednesday, US President Donald Trump signed an Executive Order imposing an additional 25% tariff on imports from India, raising the total tariff on Indian goods to 50%. According to the order issued by the White House, Trump cited matters of national security and foreign policy concerns, as well as other relevant trade laws, for the increase, claiming that India's imports of Russian oil, directly or indirectly, pose an "unusual and extraordinary threat" to the United States. After the order, the total tariff on Indian goods will be 50 per cent. While the initial duty comes into effect on August 7, the additional levy will come into effect after 21 days and will be imposed on all Indian goods imported into the US, except for goods already in transit or those meeting specific this announcement, the Ministry of External Affairs (MEA), in its response, termed the US's move as "unfair, unjustified and unreasonable", declaring that New Delhi will take "all actions necessary to protect its national interests."In an official statement, the MEA said, "The United States has in recent days targeted India's oil imports from Russia. We have already made clear our position on these issues, including the fact that our imports are based on market factors and done with the overall objective of ensuring the energy security of 1.4 billion people of India.""It is therefore extremely unfortunate that the US should choose to impose additional tariffs on India for actions that several other countries are also taking in their own national interest," the statement added."We reiterate that these actions are unfair, unjustified and unreasonable. India will take all actions necessary to protect its national interests," the MEA stressed.
Time of India
07-08-2025
- Business
- Time of India
Executive order by US administration excludes Pharma sector from immediate tariff imposition: Indian Pharmaceutical Alliance
The Indian pharmaceutical sector has been "excluded" from the immediate US tariff imposition, as generic medicines are "important" for affordable healthcare in the United States, said Sudarshan Jain, Secretary General of the Indian Pharmaceutical Alliance , on Wednesday. This comes after US President Donlad trump imposed an additional 25 per cent tariff on India over the continued purchase of Russian oil. Productivity Tool Zero to Hero in Microsoft Excel: Complete Excel guide By Metla Sudha Sekhar View Program Finance Introduction to Technical Analysis & Candlestick Theory By Dinesh Nagpal View Program Finance Financial Literacy i e Lets Crack the Billionaire Code By CA Rahul Gupta View Program Digital Marketing Digital Marketing Masterclass by Neil Patel By Neil Patel View Program Finance Technical Analysis Demystified- A Complete Guide to Trading By Kunal Patel View Program Productivity Tool Excel Essentials to Expert: Your Complete Guide By Study at home View Program Artificial Intelligence AI For Business Professionals Batch 2 By Ansh Mehra View Program Jain, says, "The recent Executive Order by the US Administration excludes the pharmaceutical sector from immediate tariff imposition. The sector is being reviewed under the Section 232 investigation. Generic medicines are important for affordable healthcare in the US and typically operate on razor-thin margins. Ensuring their consistent availability is critical for patient care" by Taboola by Taboola Sponsored Links Sponsored Links Promoted Links Promoted Links You May Like These Famous Faces Once Walked Campus Halls—Guess What They Majored In Learn More Undo " India-US partnership is key to securing API supply chains and enhancing healthcare resilience," he noted. On Wednesday, US President Donald Trump signed an Executive Order imposing an additional 25% tariff on imports from India, raising the total tariff on Indian goods to 50%. Live Events According to the order issued by the White House, Trump cited matters of national security and foreign policy concerns, as well as other relevant trade laws, for the increase, claiming that India's imports of Russian oil, directly or indirectly, pose an "unusual and extraordinary threat" to the United States. After the order, the total tariff on Indian goods will be 50 per cent. While the initial duty comes into effect on August 7, the additional levy will come into effect after 21 days and will be imposed on all Indian goods imported into the US, except for goods already in transit or those meeting specific exemptions. Following this announcement, the Ministry of External Affairs (MEA), in its response, termed the US's move as "unfair, unjustified and unreasonable", declaring that New Delhi will take "all actions necessary to protect its national interests." In an official statement, the MEA said, "The United States has in recent days targeted India's oil imports from Russia. We have already made clear our position on these issues, including the fact that our imports are based on market factors and done with the overall objective of ensuring the energy security of 1.4 billion people of India." "It is therefore extremely unfortunate that the US should choose to impose additional tariffs on India for actions that several other countries are also taking in their own national interest," the statement added."We reiterate that these actions are unfair, unjustified and unreasonable. India will take all actions necessary to protect its national interests," the MEA stressed.
Time of India
24-07-2025
- Business
- Time of India
Pharma, medical device sectors receive right prescription
This is a representative AI image The India-UK FTA is expected to strengthen supply chains for pharma and medical devices sectors, improve access to affordable medicines, and pave the way for collaboration in bulk drugs and joint research. The domestic pharma industry is hopeful exports of generic drugs to UK - currently valued at around $1 billion - will see a boost. Sudarshan Jain, secretary general, Indian Pharmaceutical Alliance, said the pact offers opportunities to supply affordable and quality-assured medicines, contributing to better patient care in the UK. Namit Joshi, chairman of Pharmexcil, added the agreement paves the way for partnerships in bulk drug imports, CDMO, and joint research, strengthening India's competitive edge. The medical devices industry also expects bilateral trade to accelerate. "Earlier, devices imported into UK were duty-free, so tariffs weren't a concern. But regulatory approval costs & timelines were. We had sought UK recognition of Indian CDSCO or QCI certifications to fast-track approvals," said Rajiv Nath, forum coordinator, AiMeD. He highlighted need for stricter Rules of Origin checks to prevent misuse of FTA. Stay informed with the latest business news, updates on bank holidays and public holidays . AI Masterclass for Students. Upskill Young Ones Today!– Join Now
News18
07-07-2025
- Health
- News18
If Vaccines Hadn't Saved Us From Covid-19, We Wouldn't Be Here To Question Heart Attacks
Last Updated: There is no conclusive proof that Covid vaccines directly caused a spike in heart attacks but we can't ignore that Covid-19 itself has left behind a legacy of cardiovascular damage The rise in heart-related complications and sudden deaths post-Covid-19 has triggered several debates, especially around the role of vaccines. Social media amplifies claims—often anecdotal, rarely scientific—linking Covid-19 vaccines to cardiac issues. But here's a fundamental question: If these vaccines hadn't been developed in record time, would we have even lived long enough to speculate on their side effects? The latest debate was triggered by a post on the social media platform X, where Karnataka's Chief Minister Siddaramaiah wrote on July 1: 'In the past month alone, in just one district of Hassan, more than twenty people have died due to heart attacks. The government is taking this matter very seriously… It cannot be denied that the hasty approval and distribution of the Covid vaccine to the public could also be a reason for these deaths, as several studies worldwide have recently indicated that COVID vaccines could be a cause for the increasing number of heart attacks…" In response, what we saw throughout last week was a coordinated and deliberate effort from the Centre, leading medical institutions, and vaccine manufacturers to rebuild and reinforce public confidence in Covid-19 vaccines. Siddaramaiah's claim was strongly rebutted, not only by government-run institutions but also by top pharmaceutical executives, researchers, and well-known doctors. Sample this: The Indian Pharmaceutical Alliance (IPA)—the lobby of domestic pharmaceutical companies representing Sun Pharma, Glenmark, Lupin, Cipla and many others—issued a strong statement supporting Covid-19 vaccines. Industry leaders like Kiran Mazumdar-Shaw of Biocon and Samir Mehta of Torrent Pharma also publicly backed vaccine safety and dismissed the unfounded claims. Top doctors from AIIMS and scientists at ICMR have taken to public platforms to bust myths and explain the science, stressing that panic must not replace facts. The Serum Institute of India (SII)—manufacturer of India's poster boy vaccine Covishield—also reaffirmed that Covid-19 vaccines are safe, scientifically validated, and critical in saving lives. Given that over 170 crore doses of Covishield have been administered out of the 200+ crore total vaccine doses in India, this clarification is not just welcome but vital. These clarifications were essential in addressing the growing public anxiety around sudden cardiac deaths, particularly among younger people. While these incidents are tragic and deserve a detailed investigation, the Union government has made it unequivocally clear: these deaths should not be automatically linked to Covid-19 vaccination. Let's understand this scientifically. As of today, there is no conclusive evidence that Covid-19 vaccines directly caused a spike in heart attacks or sudden cardiac arrests in India. However, we must not ignore a crucial truth: Covid-19 itself has left behind a legacy of cardiovascular damage. The virus is known to inflame blood vessels and affect heart muscle tissue. A 2022 study in Nature Medicine found a 63 per cent higher risk of heart attack in patients within a year of Covid infection. Multiple global studies, including those published in respected medical journals such as The Lancet and the New England Journal of Medicine, have shown that the risk of myocarditis and other heart complications is higher after a Covid-19 infection than after vaccination. A study conducted by the Indian Journal of Medical Research—a peer-reviewed publication supported by ICMR—concluded that Covid-19 vaccination was not associated with an increased risk of unexplained sudden death among young adults. On the contrary, the study documented that vaccination reduced the risk of unexplained sudden death in this age group. The Indian Council of Medical Research (ICMR) and the National Technical Advisory Group on Immunisation (NTAGI) have reiterated that adverse events following immunisation (AEFIs) remain extremely rare. India's official AEFI data shows less than 0.01 per cent serious reactions among the more than 2.2 billion doses administered. Add to this another critical factor: Indians are more genetically susceptible to heart diseases than Western populations. According to a Lancet Regional Health Southeast Asia study published in February 2023, the cardiovascular burden in India is higher than the global average. The age-standardised death rate globally is 233 deaths per 1,00,000, while for India it is 282 per 1,00,000. Yet, unfounded narratives continue to gain traction—some fuelled by misinformation, others by genuine grief seeking answers in a complex post-pandemic landscape. What the available evidence shows is that vaccines, by reducing the severity and spread of the virus, likely played a role in limiting long-term cardiovascular consequences. They weren't just about immediate survival—they bought us time and prevented the invisible wave of complications that continues to unfold. Even if science someday finds a small causal link between certain vaccines and rare cardiac events, we must remember: public health is about trade-offs. During a pandemic, decisions must be made under pressure, aiming to save as many lives as possible. Vaccines were not perfect and they were never claimed to be. What they were, and remain, is effective and life-saving on a population scale. It's also essential to acknowledge the wider ecosystem of risk: lockdown-induced sedentary lifestyles, elevated stress, mental health challenges, and delayed chronic care. And also, the genetic structure of Indians, which is vulnerable to metabolic resistance, hence, diabetes and cardiovascular diseases develop relatively easily. These all contribute to rising cardiac cases—and must be part of the conversation. Blaming vaccines alone oversimplifies a deeply layered issue. top videos View all In short, this is not a defence of pharmaceutical companies or vaccine makers who profited heavily during the pandemic, nor is it a dismissal of the real grief of those who lost loved ones. This is a call for nuance. We need to look at the full picture, not just one side of the story. Let's continue investigating, let's strengthen pharmacovigilance and monitoring across India. Remember, we are alive to debate the side effects because the vaccines worked. Get breaking news, in-depth analysis, and expert perspectives on everything from politics to crime and society. Stay informed with the latest India news only on News18. Download the News18 App to stay updated! tags : AIIMS COVID-19 vaccine covishield health matters Kiran Mazumdar-Shaw news18 specials Serum Institute of India Siddaramaiah Location : New Delhi, India, India First Published: July 07, 2025, 10:00 IST News india If Vaccines Hadn't Saved Us From Covid-19, We Wouldn't Be Here To Question Heart Attacks
Time of India
03-07-2025
- Health
- Time of India
COVID-19 vaccines well-documented, rigorously tested as per regulatory processes: IPA
The Indian Pharmaceutical Alliance (IPA) refuted claims linking COVID-19 vaccines to heart attack deaths, emphasizing their rigorous testing and crucial role in combating the pandemic. IPA Secretary General Sudarshan Jain highlighted the Indian pharmaceutical industry's knowledge-driven nature and its significant contribution to global vaccine production, accounting for 60% of the world's supply. Tired of too many ads? Remove Ads Tired of too many ads? Remove Ads New Delhi: Indian Pharmaceutical Alliance on Thursday asserted that COVID-19 vaccines have been well-documented and rigorously tested according to regulatory standards, playing a crucial role in combating the naming Karnataka Chief Minister Siddaramaiah , who linked COVID-19 vaccines with a spate of heart attack deaths in the state's Hassan district, Indian Pharmaceutical Alliance (IPA) said, "Misinformation and distortion of facts endanger public health and undermine the trust built on science and patient care globally"."During the COVID pandemic, vaccines played a crucial role, and India consistently supplied medicines and vaccines across the world. These vaccines have been well documented and rigorously tested as per regulatory processes," IPA Secretary General Sudarshan Jain said in a asserted that the Indian pharmaceutical industry is a knowledge-driven sector and plays a vital role in global health."India accounts for 60 per cent of global vaccine production ," he statement comes in the wake of Siddaramaiah suggesting that the recent heart attack deaths in Hassan district may be linked to the vaccination drive. He had also claimed the vaccines were 'hastily' in the day, Biocon founder Kiran Mazumdar-Shaw had also opposed Siddaramaiah's remarks, saying such claims are "factually incorrect" and "misleading".
